The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2023 | Challenges in selecting patients with MF for SCT & using AI to determine the optimal timing for SCT
Monia Marchetti, MD, Azienda Ospedaliera SS. Antonio e. Biagio e Cesare Arrigo, Alessandria, Italy, comments on indications for stem cell transplantation (SCT) in patients with myelofibrosis (MF), discussing the optimal timing for transplant in this setting and highlighting challenges in selecting patients for this procedure. Prof. Marchetti also comments on the potential use of artificial intelligence (AI) to determine the optimal timing for SCT in MF. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Gilead consultancy fees.
